GlassScriptPhysician profile
Jesus Rodriguez
NPI 1912622150
$4,473.66
in general payments reported to CMS, 2019-2025
29 companies · $4,474 in 2025
The $4,474 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $4,474.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,404 · Education: $69.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,403.67 |
| Education | $69.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $409.64 | 2025 | |
| Abbvie INC. | $364.86 | 2025 | |
| Ucb, INC. | $334.27 | 2025 | Fintepla, Nayzilam, Briviact |
| Emd Serono, INC. | $326.90 | 2025 | Mavenclad |
| Tg Therapeutics, INC. | $291.11 | 2025 | |
| Argenx US, INC. | $284.93 | 2025 | Vyvgart Hytrulo, Vyvgart |
| Alexion Pharmaceuticals, INC. | $257.70 | 2025 | Ultomiris |
| Otsuka America Pharmaceutical, INC. | $249.37 | 2025 | Rexulti |
| Harmony Biosciences LLC | $245.80 | 2025 | |
| Neurelis, INC. | $215.20 | 2025 | Valtoco |
| Lundbeck LLC | $163.74 | 2025 | Vyepti |
| Axsome Therapeutics, INC. | $141.66 | 2025 | Sunosi |
| Genentech USA, INC. | $139.92 | 2025 | Ocrevus Zunovo |
| Genentech, INC. | $128.29 | 2025 | Ocrevus |
| Novartis Pharmaceuticals Corporation | $120.08 | 2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sk Life Science, INC. | $103.60 | 2025 | Xcopri |
| Vanda Pharmaceuticals INC. | $101.01 | 2025 | Ponvory |
| Jazz Pharmaceuticals INC. | $99.19 | 2025 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $88.56 | 2025 | Rexulti |
| Merz Pharmaceuticals, LLC | $85.77 | 2025 | Xeomin, Inbrija |
| Abbott Laboratories | $65.12 | 2025 | Freestyle Libre 3 |
| Pfizer INC. | $64.62 | 2025 | |
| Acadia Pharmaceuticals INC | $55.04 | 2025 | Nuplazid |
| Janssen Biotech, INC. | $40.83 | 2025 | |
| Janssen Pharmaceuticals, INC | $22.70 | 2025 | Spravato |
| Ge Healthcare | $21.93 | 2025 | |
| Octapharma USA, INC. | $19.89 | 2025 | Panzyga |
| Genzyme Corporation | $16.88 | 2025 | |
| Cycle Pharmaceuticals INC | $15.05 | 2025 | Bafiertam |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jesus Rodriguez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.